William P Esler
5PUBLICATIONS
19CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Feb 16, 2024
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants.Aarti Sawant-Basak, Arthur J Bergman, Jessica Mancuso
|Dec 14, 2022
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes.Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi
|Oct 12, 2021
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.Roberto A Calle, Neeta B Amin, Santos Carvajal-Gonzalez
|Sep 15, 2020
De novo lipogenesis is essential for platelet production in humans.Kenneth L Kelly, William J Reagan, Gabriele E Sonnenberg
|May 17, 2019
Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition.William P Esler, Gregory J Tesz, Marc K Hellerstein
Pageof 1
Frequent Collaborators
2 joint publications
Albert M Kim
2 joint publications
Roberto A Calle
1 joint publications
Gregory J Tesz
1 joint publications
Raja Sivamani
1 joint publications
Santos Carvajal-Gonzalez
1 joint publications
Frank J Geoly
1 joint publications
Julie J Purkal
1 joint publications
Mark Fitch
1 joint publications
Aarti Sawant-Basak
1 joint publications
Suzana S Bosanac
